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Abstract
Inflammatory bowel disease is a group of diseases that 
includes Crohn’s disease (C�) and ulcerative colitis. C� 
is characterized as a chronic inflammatory disease of 
the gastrointestinal tract, ranging �rom the mouth to 
the anus. Although there are gross pathological and 
histological similarities between C� and Johne’s dis�
ease o� cattle, the cause o� C� remains controversial. 
It is vital to understand �ully the cause o� this disease 
because it a��ects approximately 500 000 people in 
North America and Europe. It ranges �rom 27 to 48 
cases per 100 000 people. There are many theories 
on the cause o� C� ranging �rom possible association 
with environmental �actors including microorganisms 
to imbalance in the intestinal normal flora of the pa�
tients. Regardless o� the environmental trigger, there 
is strong evidence that a genetic disposition is a major 
key in acquiring C�. Many studies have proven the link 
between mutations in the AT�16L , NO�2/CAR�15 , 
IB�5 , CTLA4 , TNFSF15  and IL23R genes, and C�. The 
purpose o� this review is to examine all genetic aspects 
and theories o� C�, including up to date multiple popu�
lation studies per�ormed worldwide.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
The first description of  Crohn’s disease (CD) was made 
in 1769 by an Italian physician, Giovanni Battista Mor-
gagni, when he diagnosed a man with chronic diarrhea. 
In 1898, consecutive cases were reported by John Berg, 
and then in 1904 by Antoni Lesniowski. Throughout the 
1920s and 1930s, young adults were thought to have this 
same condition as they suffered from symptoms, such as 
abdominal cramps, diarrhea, fever and significant weight 
loss. In 1923, surgeons at Mt. Sinai Hospital in New 
York had also identified patients with comparable symp-
toms. In addition, in 1930, Dr. Burrill B Crohn saw a 
connection between this unknown debilitating condition 
and two of  his patients. Consequently, Dr. Crohn and his 
World J Gastroenterol  2012 February 7; 18(5): 412-424
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2012 Baishideng. All rights reserved.
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v18.i5.412
412 February 7, 2012|Volume 18|Issue 5|WJG|www.wjgnet.com
Naser SA et al . �enetics in Crohn’s disease
colleagues presented a paper in 1932, “Regional ileitis: a 
pathologic and chronic entity”, describing the features 
of  this disease to the American Medical Association. CD 
was named after Burrill Crohn and it became an official 
medical entity in 1932. 
CD is a chronic inflammatory disease that can affect 
any portion of  the digestive tract including the mouth, 
esophagus, and small and large intestines, but is most 
common in the ileum. It is also characterized as an au-
toimmune disease in which the body attacks itself  and 
causes inflammation. In its mild form, it causes erosions 
called aphthous ulcers in the inner surface of  the bowel. 
In severe cases, deeper and larger ulcers develop that can 
lead to bowel obstruction and holes in the bowel wall. If  
a hole in the bowel wall arises, infection to neighboring 
organs can occur. CD branches off  to many forms de-
pending on the location of  erosion. If  these symptoms 
take place within the large intestine, it is called Crohn’s or 
granulomatous colitis. If  it occurs in the small intestine, 
it is known as Crohn’s enteritis, and more specifically if  
it occurs in the ileum, it is called Crohn’s ileitis. During 
severe cases in which the small and large intestine are 
both involved, it is known as Crohn’s enterocolitis or 
ileocolitis. CD is separated into three phenotypes: non-
stricturing and non-penetrating, stricturing and penetrat-
ing CD[1,2].
CD is most prevalent in North America and Europe, 
and least prevalent among African Americans and Asians[3]. 
It affects approximately 500 000 people in North America 
and Europe. It ranges from 27 to 48 cases per 100 000 
people. There is no difference in prevalence among males 
or females. Individuals with siblings affected by CD have 
a higher risk of  acquiring the disease. There is evidence 
of  a cause from environmental factors, thus, there are a 
higher number of  cases in western industrialized countries. 
Symptoms of  CD typically begin in the teens and twenties 
and then go into remission on and off  with appropriate 
therapies. There is a peak incidence between 50 years and 
70 years of  age, which often leads to major complications 
due to age and the necessity of  surgery. 
Although the etiology is still unknown, there are 
many theories about what causes CD and ulcerative 
colitis (UC). Many believe it is caused by environmental 
factors, such as certain foods, bacteria, viruses, or ciga-
rette smoke, which all can trigger an immune system 
response. Scientists have linked inflammatory bowel 
diseases (IBDs) as an autoimmune problem. In a healthy 
person, the immune system defends the body against 
harmful microbes that have entered it. Upon triggering 
the immune system, an inflammatory response occurs 
in which immune cells aggregate at the site of  infection 
and overcome the threat. There are microbes native to 
our bodies that are useful rather than harmful to which 
the immune system does not trigger a response. In pa-
tients with CD, the immune system will attack these na-
tive luminal bacteria, disrupting the normal flora, thus 
characterizing this condition as an autoimmune disease. 
Recent research has indicated specific genetic varia-
tions as a direct cause of  CD and UC. The genetic aspects 
of  CD have been linked by observing familial cluster-
ing of  IBD cases[4]. Genetic variations in the ATG16L, 
NOD2/CARD15 and IL23R genes have strongly been 
linked to the onset of  CD[5]. Not only are individual gene 
mutations listed as a cause of  CD, but a combination of  
them has also been shown in CD patients by conduct-
ing many population studies. There have also been many 
studies that have predicted surgical outcomes in both 
adults and children with specific genetic variations.
Diagnosis of  CD can be tricky and requires a num-
ber of  tests to be certain. Colonoscopy is the most ef-
fective way to diagnose CD but not in all cases because 
it only allows the physician to visualize the colon, ileum, 
and lower portion of  the small intestine[6]. If  the ul-
cers are located within the upper portion of  the small 
intestine, this test will not be effective. In this case, a 
barium follow-through X-ray is useful because barium 
sulfate gives fluoroscopic images of  the bowel and the 
physician can see areas of  inflammation and narrow-
ing[6]. Another effective method of  diagnosis is the use 
of  white blood cell scans. During this procedure, white 
blood cells are tagged with a radioisotope and then 
injected back into the patient. At specific intervals of  
time, the scan can locate accumulations of  white blood 
cells in the intestine at the site of  CD. This method is 
also useful to monitor the disease and show effective-
ness in other therapies. Furthermore, a simple blood 
test can also diagnose CD because it can determine 
whether the patient is anemic or has a vitamin B12 defi-
ciency because vitamin B12 is absorbed in the ileum and 
a deficiency can be due to ileitis.
CD causes a wide variety of  symptoms and can be 
confused with UC, which is a similar disease, both under 
the group of  IBDs. UC is only found in the colon and 
affects the mucosal membrane, whereas CD can occur 
anywhere throughout the gastrointestinal (GI) tract and 
affects the thickness of  the GI wall. Individuals with CD 
can experience flare-ups followed by remissions. It can 
vary from one flare-up in a lifetime to multiple flare-ups 
that need surgical treatment. Symptoms include persis-
tent diarrhea, abdominal pain in the affected area, fever, 
and weight loss[6]. There are also signs and symptoms 
that may occur unrelated to the GI tract, such as redden-
ing and inflammation of  the eye, joint pain, skin lesions, 
and sores inside the mouth. 
Currently, there is no cure for CD. Treatment is fo-
cused on relieving the symptoms and putting it into re-
mission. Since CD is characterized as an autoimmune dis-
ease, medications to suppress the immune system include 
5-aminosalicylic acid and steroids, such as prednisone[6]. 
Antibiotics such as clarithromycin, ampicillin and metroni-
dazole, can also be used. More than 50% of  patients with 
CD will have to undergo surgical treatment to correct 
a fistula, drain an abscess, open a narrow or obstructed 
bowel, or remove a segment of  infected intestine. 
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AUTOPHAGY-RELATED	16-LIKE	1	
PROTEIN	COMPLEX
Autophagy is a catabolic process of  intracellular degra-
dation in which cytoplasmic components are sequestered 
within vesicles and delivered to the lysosomes. Cells use 
this pathway during nutrient starvation because they 
can break down non-vital components and use them 
as nutrients. Autophagy plays a role during infection by 
helping rid the cell of  foreign antigens by breakdown of  
the pathogen. This pathway can also be implemented as 
a repair mechanism to degrade damaged organelles and 
proteins. Autophagosomes, formed by the fusion of  ly-
sosomes and vesicles, are also implicated in the process-
ing of  intracellular bacteria. If  the gene responsible for 
autophagy is mutated, it can cause a shift in normal flora 
as previously mentioned, and lead to many GI problems, 
which has been pointed out as a possible cause of  CD. 
If  the cell cannot regain nutrients or fight off  foreign 
antigens within the GI tract, these cells will undergo 
programmed cell death and cause tissue damage. This 
damage can be seen as lesions and ulcers within the in-
testines, creating dead infected patches of  tissue along 
the GI tract. The only option of  treatment is surgery to 
remove the sections of  the intestines with the diseased 
tissue so that the necrosis will not spread among neigh-
boring cells. 
An autophagosome, a double-membraned vesicle 
formed by autophagy, envelops part of  the cytoplasm 
and delivers it to the lysosomes where it is degraded and 
recycled. There have been approximately 30 autophagy-
related (Atg) genes identified, with two proteins having 
ubiquitin-like characteristics, Atg12 and Atg8[7]. These 
proteins covalently modify their target protein with 
molecules such as ubiquitin-like proteins to tag them 
for degradation. Both proteins also contain a conserved 
ubiquitin-fold region[7]. Autophagosomes use two con-
jugation systems, the Atg12 and LC3-Ⅱ systems[8]. 
These systems were first discovered during yeast genetic 
studies revealing a set of  17 ATG genes involved in the 
autophagy pathway[9]. In the Atg12 conjugation system, 
an Atg12-Atg5-Atg16L complex forms, and dissociates 
from the membrane just before or after completion 
of  the autophagosome[8]. The ATG16L1 protein is ex-
pressed in the colon, small intestine, intestinal epithelial 
cells, leukocytes, and spleen[8]. Recent independent stud-
ies have shown that an ATG16L mutation, located on 
chromosome 2, is associated with the onset of  ileal CD, 
and is therefore a key molecule in elucidating the genetic 
aspects of  this disease[10].  
Multiple studies have been performed with each re-
sulting in the same conclusion that ATG16L is implicat-
ed in CD. During a genome-wide survey of  19 779 non-
synonymous single nucleotide polymorphisms (SNPs), 
Thr300Ala within the N terminus of  ATG16L was 
found to be highly associated with CD by using a hap-
lotype and regression analysis[4]. This study used a total 
of  735 CD patients, 368 controls and 72 SNPs. A sec-
ond report from the North American CD genome-wide 
study submitted by Rioux and colleagues also shows an 
association with ATG16L using a case-control analysis 
in 988 CD patients and 1007 controls[11]. Another group 
of  German and British collaborators demonstrated that 
rs2241880, another non-synonymous variant of  the 
ATG16L gene on chromosome 2q37.1, is implicated in 
the autophagy pathway[8].  
In a study performed on an Italian cohort, the same 
polymorphism, rs2241880, was observed in 667 CD and 
668 UC patients[12]. Both the frequency of  the G allele 
and number of  carriers of  the G allele were increased 
in CD patients when compared to the controls[12]. These 
differences were only significant in the adult subgroup, 
which could be due to the small sample size of  the pe-
diatric subgroup. In comparison, there were no signifi-
cant allele or genotype frequencies found between UC 
patients and controls for the groups as a whole[12]. Dur-
ing analysis of  genotype/phenotype correlation of  the 
rs2241880 SNP, there were no associations with disease 
location, behavior, and age at diagnosis based on the 
Montreal Classification of  CD[12]. There were also no as-
sociations found in sex, smoking, and perianal fistulae[12]. 
For the rs2241880 variant, recent studies, specifically 
by Prescott[13], demonstrate an association with the ileal 
form of  CD with or without colonic involvement, but 
not with isolated colonic disease[12]. 
In addition, a study from Oxford compared 645 CD 
patients with 1190 controls and showed an associa-
tion of  ATG16L1 with CD[14]. To understand fully 
the function of  this gene, a study utilized oligo-based 
silencing RNA directed against ATG16L1 isoforms, 
where autophagy was induced by Salmonella typhimurium 
in ATG16L1 knockdown HEK293 cells. There was a 
significant difference between the knockdown cells 
com-pared to the control cells during the autophagy path-
way[11]. It is clear to say that variants of  this gene have 
been proven without a doubt to be directly associated 
with CD because autophagy plays a critical role in dis-
ease pathogenesis. Further research needs to focus on 
understanding how ATG16L1 variants contribute to 
disease susceptibility in IBD patients, and their possible 
therapeutic implications. 
TUMOR	NECROSIS	FACTOR	SUPER	
FAMILY	15
Tumor necrosis factor super family 15 (TNFSF15) is a 
Th-1 polarizing cytokine involved in systemic inflam-
mation. TNF functions to regulate immune cells, induce 
apoptosis, induce inflammation, and inhibit tumorigen-
esis. TNFs are produced by macrophages, lymphoid 
cells, mast cells and endothelial cells. During immuno-
logical studies, it has been found that CD patients have 
an increased expression of  TNFSF by multiple cells in 
the intestinal tissues when compared to controls[7]. The 
TNFSF15 gene is a candidate for increased susceptibility 
in IBD. It binds to a specific T-cell receptor to enhance 
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cytokine-induced interferon expression in mucosal CD4+ 
T cells[7]. 
In 2005, the first genome study involving IBD tested 
nearly 80 000 SNPs in Japanese CD patients. This study 
identified haplotypes within the TNFSF15 gene, which 
included seven SNPs within a 280-kb region on chro-
mosome 9q32[15]. By resequencing TNFSF15 from the 
same CD cases but with a new control group, TNFSF15 
was found to be strongly associated with CD with an 
odds ratio (OR) of  2.17 (95% CI: 1.78-2.66), P = 1.71 × 
10-14[15]. The Japanese wanted to see if  the same patterns 
were seen in other population groups so they replicated 
their associate in two panels from Oxford, United King-
dom. Although the risk haplotype was identified in both 
cohorts, there was a weaker effect size (P = 0.02 in both 
family-based and case-control association panels). In 
addition, another study involving a Jewish cohort also 
showed an association of  TNFSF15 with CD, and also 
suggested that in response to FC-gamma receptor stimu-
lation, TNFSF15 gene variation aggravates induction of  
TNFSF15[16]. However, in a separate study using a Bel-
gian CD cohort, no significant association was observed 
between CD and TNFSF15[4]. This may have been due 
to different marker genotypes or differences in suscep-
tibility genes between Asian and European cohorts[4]. 
Not enough studies have been performed regarding 
TNFSF15 and its possible implications in CD. Future 
studies have to focus on different populations to provide 
efficient insight. 
NOD2/CARD15	GENE
Nucleotide-binding oligomerization domain containing 
2 (NOD2), located on chromosome 16q12, is a protein 
that plays an essential role in the immune system by 
controlling commensal bacterial flora in the intestine[17]. 
NOD2 belongs to a nucleotide-binding domain, leucine-
rich repeat family of  cytoplasmic proteins that may 
detect a variety of  bacteria by acting as an intracellular 
sensor for bacterial peptidoglycan[18]. It has the ability to 
respond to N-acetylmuramyl-L-alanyl-D-isoglutamine 
(MDP) via the leucine-rich repeat domain. The MDP is 
conserved in both Gram-negative and positive bacte-
ria[10,19]. This leucine-rich repeat domain plays a role in 
protein-protein interactions and the middle portion of  
the protein is responsible for self-oligomerization. The 
N-terminal portion of  NOD2 contains two caspase re-
cruitment domains (CARDs) which play a role in apop-
tosis. The CARD15 gene, which encodes for the CARD 
domain within NOD2, has been specifically identified 
as a genetic factor for CD. Three SNPs were found 
to be independently associated with CD: rs2066844, 
rs2066845, and an insertion mutation 3020insC[20]. Each 
variant may result in distinct phenotypic expression of  
CD[4]. To activate NOD2, Rip2 kinase is required be-
cause it is necessary for downstream signaling of  NOD2 
and signaling cascades such as nuclear factor (NF)-κB 
and mitogen-activated protein kinase cascades[21]. 
The intestinal mucosa is constantly exposed to a large 
number of  commensal microorganisms; the majority of  
which inhabit the large intestine. In a healthy individual, 
there is a basal immune response elicited from the in-
teraction between the intestinal immune system and 
commensal bacteria. This immune response is constantly 
present to protect the host from pathogenic and non-
pathogenic bacteria. When there are changes within this 
balance, the intestines are susceptible to chronic intes-
tinal inflammatory conditions, such as CD[21]. Multiple 
genetic studies have linked NOD2 with susceptibility 
to CD. However, NOD2-deficient mice do not develop 
colitis, suggesting that dysregulation of  the NOD2 
pathway is not sufficient to provoke CD[22]. This is not 
a surprise because the pathogenesis of  CD is caused by 
several factors including environmental, dysfunctional 
immune system, and a shift in normal bacterial flora[21]. 
NOD2 is expressed in Paneth cells, which are found 
in the intestines. The exact functions of  Paneth cells are 
still unknown, but they are likely to contribute to the 
host defense by secreting antibacterial compounds due 
to the presence of  lysozyme. A NOD2 mutation can 
alter the function of  Paneth cells, which alters their an-
timicrobial activity and leads to the development of  ileal 
lesions, which correspond to the location of  these cells. 
Of  the three NOD2 mutations associated with CD, both 
rs2066844 and rs2066845 are the result of  a two-amino-
acid substitution in which rs2066844 is encoded by exon 
4 and rs2066845 is encoded by exon 8[23]. The variant 
1007fs is created by a frameshift mutation in exon 11[23]. 
Each of  the three mutations occurs within or near the 
leucine-rich repeat and decrease the cells ability to ac-
tivate NF-κB in response to peptidoglycan[18]. Interest-
ingly, these mutations are observed in Caucasian patients 
but not in Japanese, Chinese and Korean patients with 
IBD, and they are very rare in African Americans with 
IBD[24,25]. An individual heterozygous for at least one 
NOD2 mutation is at a 2-4-fold increased risk of  devel-
oping CD, whereas a homozygous individual for at least 
one NOD2 mutation is at a 20-40-fold increased risk 
when compared to healthy individuals[14]. 
Studies of  each individual mutation in NOD2 have 
shown that 1007fs causes a decrease in defensin expres-
sion[26]. Defensins are cells of  the immune system that 
assist in killing phagocytized bacteria. They function by 
binding to the microbial cell membrane and forming 
a pore in the membrane that allows outward flow of  
nutrients and essential ions. CD patients who are homo-
zygous and/or heterozygous for NOD2 mutations typi-
cally have lower defensin levels in their ileostomy fluid[17]. 
As a result of  a mutation in NOD2, the function of  this 
protein is diminished, therefore allowing subsequent 
entry of  bacteria into epithelial cells because they are 
no longer able to recognize them. This in turn alters the 
bacterial population in the intestines and thus, defensins 
are not able to function correctly because they are work-
ing in an impaired bactericidal capacity[22].  
In a recent study by Van Limbergen et al[17], it was 
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were heterozygous for at least one NOD2 mutation: 
17.2% for rs2066844, 9.6% for rs2066845, and 11.7% 
for 1007fs[14]. In conclusion, the genetic alterations were 
observed more predominantly in German pediatric CD 
patients than in adults. The study also looked into each 
mutation and its association with localization and symp-
toms of  the disease. A 4.73-fold increased risk of  iso-
lated ileal localization was observed in patients that were 
identified as 1007fs carriers when compared to children 
with none of  the NOD2 mutations[14]. Although the 
1007fs carriers were predisposed to ileal disease, there 
was no involvement of  the ileocolonic or upper GI 
tract[14]. The next characterization the study explored 
was the association of  NOD2 mutations and strictur-
ing disease or perianal fistulae in their German pediatric 
CD cohort. Only 17% of  patients showed a stricturing 
phenotype and 18.1% had a perianal fistula[14]. Among 
the children that showed a stricturing phenotype, 79.3% 
required surgery and those with the 1007fs mutation had 
surgical complications[14]. The outcome showed a 9.8-fold 
increase in surgical complications when the child carried 
at least one allele for the 1007fs mutation[14]. Not only 
is the 1007fs mutation strongly associated with isolated 
ileal disease, but children are at a high risk for surgical 
intervention. Therefore, this mutation can act as a prog-
nostic tool in Caucasian children with CD[14]. 
Another study by Jurgens and colleagues has investi-
gated the presence of  fistulas and their association with 
NOD2 homozygosity and how they predict intestinal 
stenosis in CD patients. It was observed that patients 
with fistulas had simultaneous intestinal stenosis[15]. In 
another study using the same research, it was found that 
NOD2/CARD15 variants, especially with 1007fs ho-
mozygosity, could predict the occurrence of  intestinal 
stenosis[27]. By using a strict screening process based on 
phenotypes including stenoses (stricturing CD) and fis-
tulae (penetrating CD), and genotype, the study isolated 
a total of  145 patients. One hundred and twenty-five 
of  the patients had penetrating CD with simultaneous 
stenosis within a 6-mo interval[28]. It was also found 
that all 14 CD patients homozygous for NOD2 vari-
ants suffered from stenosis[28]. To no one’s surprise, 11 
out of  the 14 patients with stenosis and fistulas carried 
the NOD2 1007fs mutation[28]. These data confirm the 
strong risk factor of  the 1007fs NOD2 mutation in the 
prevalence of  intestinal stenosis, which may be related 
to the decreased intestinal barrier function found in CD 
patients with NOD2/CARD15 variant mutations[28]. 
This study has isolated the 1007fs variant as the cause 
in disrupting the intestinal barrier and causing the many 
problems often observed in CD patients. 
To investigate whether stenosis occurs in a specific 
anatomical region, 223 patients with 248 stenoses located 
at different intestinal regions were examined[28]. The most 
common anatomical region was the terminal ileum with 
68.8% of  stenoses, followed by 11.7% found in the recto-
sigmoidal segment, and 9.3% in the jejunum or proximal 
ileum[28]. In conclusion, homozygosity in the NOD2/
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proven that NOD2 is required for the regulation of  
commensal microbiota in the intestine. The regulation 
of  NOD2 depends on the downstream kinase Rip2 be-
cause Rip2-deficient mice fail to establish and regulate 
commensal bacteria in their terminal ileum. NOD2-defi-
cient mice do not develop spontaneous intestinal inflam-
mation. In conclusion, the NOD2–Rip2 pathway is criti-
cal for the regulation of  homeostasis between the body’s 
normal bacterial flora and innate immunity[17]. As a con-
trolled balance, it has been found that the expression of  
NOD2 and Rip2 is dependent upon and regulated by the 
presence of  commensal bacteria[17]. This creates a nega-
tive feedback by which the commensal bacteria positively 
regulate NOD2, and in turn negatively regulate the nor-
mal flora. NOD2 mutations directly affect the ileum in 
CD patients, thus, it is possible that they are responsible 
for the composition of  the bacterial flora in the terminal 
ileum[17]. This may facilitate both disease pathology and 
progression. 
Although the exact mechanism by which NOD2 con-
tributes to the control of  commensals in the intestines 
is still not known, there are many possible theories pro-
posed by this study. The first theory entertains the possi-
bility that NOD2 regulates the commensal flora through 
the bactericidal activity of  ileal crypt secretions[17]. The 
second theory is that NOD2 regulates the adaptive im-
mune system by inducing lymphoid tissue genesis[17]. 
The third theory describes how NOD2 expression in 
myeloid lineage cells contributes indirectly to maintain 
the normal microbiota flora[17]. The fourth theory states 
that there may be other cells in the intestines, in addition 
to Paneth cells, that may play a role in the regulation of  
commensal bacteria in the intestines[17]. Further research 
is needed to elucidate this mechanism. 
It has been reported that both adults and pediatric 
cohorts share a strong association between the NOD2 
variants and ileal disease location[23]. Some studies have 
suggested that adult patients show a correlation in fibro-
stenotic behavior and NOD2 mutation status, whereas 
other studies have failed to replicate the same phenotypic 
effect[12]. It is necessary to study different CD cohorts 
from different countries to obtain an accurate effect of  
each mutation. Exploring the genotype-phenotype inter-
actions in children is beneficial because they show a high-
er gene dosage and have less environmental influences. 
A study by Lacher and colleagues has explored the 
association of  the NOD2 mutation in German pediatric 
CD patients and the risk of  surgery. The risk of  sur-
gery in children is important to predict because surgery 
is sometimes the only method of  treatment. Out of  
171 young CD patients, 78 (45.6%) carried at least one 
NOD2 mutation, with 11 being compound heterozy-
gous, and 14 being homozygous for two NOD2 muta-
tions[14]. The presence of  rs2066844 was found in 29 
(17%) children, rs2066845 was found in 18 (10.5%), and 
1007fs was found in 42 (24.6%)[14]. Overall, one out of  
three German children with CD had at least one NOD2 
mutation. In comparison, 36% of  adult CD patients 
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CARD15 mutation is a strong risk factor for intestinal 
stenosis[28]. When the study looked into the possible asso-
ciation between stenosis and interleukin-23 receptor (IL-
23R mutation variants, there was a weak connection with 
no influence on stenosis[28]. This study suggests classifying 
CD into four disease phenotypes instead of  the current 
three in the Montreal Classification System. The four new 
classifications would be: non-stricturing[12], non-fistulizing 
CD[12]; stricturing, non-fistulizing CD[18]; non-stricturing, 
fistulizing CD[29]; and stricturing, fistulizing CD[28]. It is 
important to link any possible association between fistulas 
and stenoses because there is a strong risk factor for re-
currence of  CD after surgery[28]. 
Many studies have investigated North American, Eu-
ropean and Asian countries and their CD patients with 
specific genotypes. Interestingly, the NOD2/CARD15 
mutations are very rare and even absent in Asians (Japa-
nese, Chinese and Korean), Arabs, Africans and African 
Americans[28]. A study by Baptista and colleagues has 
concentrated on a South American population for the 
first time. There were a total of  187 CD patients used 
for the study with a median age of  33 years and a me-
dian age of  onset of  23 years[24]. Their patients were 
ethnically classified into the following groups: 58.8% 
were in the Brazilian subgroup, 36.9% shared a common 
European ancestry and were in the European-Brazilian 
subgroup, three were Amerindian-Brazilian, and two 
were Afro-Brazilian[24]. The alleles related to CD within 
the CARD15, rs2066844 and 3020insC variants were 
significant for CD susceptibility[24]. Both the rs2066845 
and 1007fs variants failed to show any significant as-
sociation[24]. Among their patients, 30% had at least 
one NOD2/CARD15 variant allele[24]. The frequency 
of  rs2066844 (9.63%) in the Brazilian CD cohort was 
consistent with the reports for European populations[24]. 
In conclusion, this study confirmed that CARD15 vari-
ants lead to greater susceptibility to CD in the Brazilian 
population[24]. 
INTERLEUKIN-23	RECEPTOR	
IL-23R is a protein consisting of  an IL-12β1 and an IL-
23R chain[27]. The molecular location of  the IL23R gene 
is on chromosome 1 and is formed by the binding of  IL-
12p40 and a p19 protein[30]. It is highly expressed on the 
cell membrane of  memory T cells and other immune 
cells, such as natural killer cells, monocytes, and dendritic 
cells, which identify foreign substances to defend the 
body against infection. It is highly involved in the media-
tion of  proinflammatory activities by the production of  
IL-17 via the activation of  Th17 lymphocytes[20]. IL-23R 
interacts with IL-23, which is a cytokine that regulates the 
activity of  immune cells and plays an important role in 
the inflammatory response against infection by bacteria 
and viruses. It also has been suggested that the functional 
IL23R pathway polymorphisms play a role in modulating 
neonatal development of  intestinal tolerance and bacte-
rial colonization[4].  
Th-17 lymphocytes are a distinct subset of  T-helper 
cells, which mainly produce IL-17 and to a lesser extent 
IL-6 and TNF-α[26]. IL-17 in vitro and in vivo acts as a 
potent inflammatory cytokine and is involved in the de-
struction of  cartilage and bone, as seen in rheumatoid 
arthritis[12]. It has been reported that IL-23 could be a 
key regulator in the differentiation of  Th-17 lympho-
cytes from memory T cells. It also has been suggested 
that IL-23 plays a role in providing a survival advantage 
to already differentiated Th-17 cells[21]. The expression 
of  the heterodimeric receptor complex, IL-23R and IL-
12Rβ1, regulates activities of  IL-23[12]. Therefore, the 
IL-23-IL17 cytokine axis is a key pathogenic mechanism 
that mediates the development and progress of  inflam-
mation by Th-17 cells. The role for the IL23-IL17 axis 
in CD patients was supported in human patients and 
animal models of  colitis[31]. Both cytokines are increased 
in knockout mouse models of  IBD. More specifically, 
IL-17 levels are increased in both intestinal mucosa and 
in the serum of  CD patients[12]. In a study using IL-
17R knockout mouse models, an association was found 
with colitis and disease severity[27]. Therefore, the use of  
anti-IL-12p40 antibody to treat CD patients is a thera-
peutic option because it is known to reduce production 
of  IL-23 and IL-17 in the lamina propria cells[12]. The 
mechanism of  IL-23R is clearly important to understand 
because it is directly associated with CD. 
During a genome-wide association study, 2877 DNA 
samples from IBD patients (two-thirds CD and one-
third UC), identified rs11209026 as a possible protective 
variant, in the IL23 gene on chromosome 1p31[4]. There 
are many other variants within IL23R that are associated 
with IBD, but rs11209026 has the strongest association 
with conferring protection against CD[4]. Although the 
effect of  IL23R variants is greatest in CD, it may have 
an overall effect on susceptibility to chronic intestinal 
inflammation.
Additional studies have confirmed the susceptibility 
of  the IL23R gene to CD in North American and Eu-
ropean populations. They include cohorts ranging from 
Scottish pediatric IBD, Belgian CD and an independent 
cohort of  883 families[4]. Due to the role of  IL-23 in ac-
tivation of  inflammatory responses, targeting this path-
way may be a good therapeutic approach. Some promis-
ing research is underway using anti-p40, which blocks 
IL-23 and IL-12 activities. The variant allele, rs11209026, 
could be exploited to define clinical outcomes, such as 
a pharmacological approach to mimic the rs11209026 
polymorphism[4]. 
A study by Schmechel and colleagues has shown 
a link in susceptibility to CD with Th17 cell function, 
IL-22 serum levels, and IL23R genotype. IL-22 is a 
strong activator of  proinflammatory gene expression and 
upregulates SOC3 mRNA in intestinal epithelial cells[29]. 
Recent evidence has shown that Th17 cells expressing 
IL23R play a key role in the mechanism by which IL23R 
modulates IBD susceptibility[32]. Previous studies have 
shown that Th17 plays a role in autoimmune diseases, 
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such as rheumatoid arthritis and CD. However, Th17 is 
responsible for the important function of  antimicrobial 
immunity at epithelial barriers where it produces cyto-
kines such as IL-22. Because it produces IL-22 in epi-
thelial barriers such as in the intestines, theoretically by 
testing for increased IL-22 serum levels, a physician can 
determine CD and disease activity. 
It has been confirmed that IL-22 serum level is in-
creased in CD and correlates with disease activity[33]. 
IL-22 serum levels are also independent of  CD phe-
notype and CARD15 genotype, but are modulated by 
IL23R polymorphisms[33]. The study investigated IL-17 
serum because Th17 cells also produce IL-17. There was 
no correlation between IL-22 and IL-17 serum levels[33]. 
Currently, serum levels of  TNF-α and IL-6 are used as 
inflammation markers in determining CD. There was 
no difference in TNF-α and IL-6 levels whether CD 
was active or in remission, whereas IL-22 levels were 
significantly higher in active CD compared to CD in 
remission[33]. Therefore, measuring IL-22 levels are clini-
cally relevant in determining the disease activity in CD 
patients[33]. 
There are also strong associations between IL-22 
serum levels and IL23R gene variants. Previous stud-
ies have shown both protective and inducing variants 
of  IL23R in susceptibility to CD. Although rs1004819 
is the CD increasing variant of  IL23R, rs11209026 has 
shown to be a protective IL23R variant against CD. 
As predicted, when the IL-22 mean serum levels were 
tested against each variant, the serum levels were highest 
among SNPs that increased CD risk as opposed to the 
identified protective SNPs of  IL23R, which had low se-
rum levels[33]. In contrast, the three main variants within 
NOD2/CARD15 did not show any differences in IL-22 
serum levels[33]. Although, the exact function of  IL-22 
in human IBD is still unknown, recent studies have ob-
served increased β-defensin-2 expression and intestinal 
epithelial cell migration and proliferation upon stimula-
tion with IL-22[29]. These data ultimately suggests a clini-
cally useful marker to assess disease severity and Th17 
cell activity in CD patients[33]. 
As mentioned above, a rare glutamine allele, rs11209026, 
in IL23R conferred protection against CD during a re-
cent genome-wide association study. Recent studies have 
proven that this variant protects against CD in both Jew-
ish and non-Jewish populations. In addition, in a study 
involving IBD (both UC and CD) patients of  Spanish 
Caucasian origin, the rs11209026 variant was seen to be 
most significantly associated with IBD protection (OR: 
0.4; 95% CI: 0.3-0.7)[34]. A study by Dubinsky and col-
leagues has investigated this rare allele further and how it 
protects pediatric CD patients. They used the transmis-
sion disequilibrium test (TDT) analysis and genotyping 
of  whole blood samples from children with IBD and 
their two parents. This rare rs11209026 SNP was present 
in 2.67% non-Jewish CD patients and 2.94% of  non-Jew-
ish UC patients[35]. The TDT demonstrated that the allele 
was under-transmitted in all CD offspring and confirmed 
the negative association between rs11209026 and CD[35]. 
Another way to confirm the association of  alleles 
with CD and UC is to use a population that is geneti-
cally isolated, such as the Finnish population. This will 
provide an advantage in molecular genetic studies in 
complex disorders[36]. A study by Lappalainen has used 
such a strategy to confirm the association of  IL23R, 
TNFRSF1A, and the HLA-DRB1*0103 allele variants. 
The strongest association of  IL23R with the marker 
rs2201841 (IL-23R risk variant) showed a frequency 
of  37.2% in CD. In most studies, the non-synonymous 
SNP, rs11209026 (the protective IL23R allele), has had 
the highest association, but is only marginally associated 
with Finnish CD[36]. No association has been observed 
between the IL23R markers and UC patients[36]. 
Previous studies have shown that the HLA-DRB1*0103 
allele is associated with both UC and CD. In the Finnish 
population, this allele only has a frequency of  0.6%, which 
is not statistically significant, whereas it is significant 
for UC and IBD[36]. When looking into the genotype-
phenotype association, patients carrying the rare HLA-
DRB1*0103 allele have colonic involvement in CD[36]. 
During the TNFRSF1A analysis, the investigators geno-
typed a rare A36G variant and an IVS6+10A (rs1800693) 
variant. CD patients with both variants often show 
ileocolonic disease in comparison with patients without 
these two variants[36]. The weak association is probably 
due to the small sample size. Interestingly, when the 
protective haplotype of  IL-23R (described in the above 
paragraph) was sequenced and compared to North 
American Caucasian CD patients, there was a one-nu-
cleotide difference between Finnish (CCTGATCG) and 
North American (CGTGATCG) CD patients[36]. In con-
clusion, the HLA-DRB1*0103 allele has been confirmed 
in CD patients, which shows an inherited susceptibility 
of  colonic inflammation. The TNFRSF1A gene vari-
ants are markers of  ileocolonic involvement in CD[36]. 
Although this study shows a weaker association of  the 
IL23R gene, it confirms the genetic involvement within 
a Finnish population.
In another population study among French-Canadian 
and English-Canadian children, the association between 
genetic variants of  the IL23R gene and early-onset of  
CD has been investigated. To study the associations ac-
curately, they have carried out both a case-control and a 
family-based study. They have targeted the 10 SNPs in 
IL23R achieved by the genome-wide study and the three 
CARD15 SNPs. In total, 259 CD patients and 139 con-
trols were recruited with a mean age at diagnosis of  13.3 
years (range: 2.6-20 years)[12]. The IL23R protective allele, 
rs11209026, was only present in 2% of  CD case chro-
mosomes and 6% of  the control chromosomes[12]. All 
CARD15 variant allele frequencies were higher among 
CD patients when compared to the control group[12]. In 
the IL23R gene, they observed a significant association 
among four SNPs that did not posses any CARD15 vari-
ants[12]. Therefore, variants in the IL23R gene were as-
sociated with early-onset CD among Canadian children. 
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This study confirms previously reported findings in CD 
patients among North Americans.   
In continuation of  a study that was described in the 
ATG16L section of  this paper, Latiano and colleagues 
have shown that the replication of  IL23R is associated in 
adult and pediatric onset of  IBD in Italy. Approximately 
730 CD patients were genotyped for the rs7517847 and 
rs11209026 variants. For the rs7517847 polymorphism, 
significant reductions were found in minor allele (G) fre-
quency in CD patients when compared with controls and 
in the number of  carriers[12]. No differences were found 
in UC patients. When the rs11209026 polymorphism 
was examined, a significant increase in the frequency of  
the risk genotype was observed in CD patients. In either 
SNP, there were no correlations between phenotypes of  
CD and risk alleles or genotypes of  the IL23R gene. 
To specify which IL23R variant is the main disease 
associated variant, a study using German CD patients 
was conducted. Among all 10 IL23R SNPs, they chose 
to focus their study on the rs1004819 variant because it 
had the strongest association to CD when compared to 
controls. This variant showed high prevalence of  ileal 
involvement when carriers had the TT genotype versus 
the CC wild-type genotype[28]. This identification is dif-
ferent from recent data published by Roberts et al[37], 
which have identified the rs7517847 variant as having the 
strongest association with CD, along with other overlap-
ping North American study populations. They have only 
analyzed ileal cases of  CD, therefore, it is assumed that 
IL23R variants are predisposed to an ileal disease pheno-
type[37]. In a recent British study, they could not identify 
any association between disease phenotype and IL23R 
variants[9]. Interestingly, they found that the rs1004819 
variant was 1000-fold weaker than that reported in the 
German study.  
Not only are the IL23R variants highly associated 
with CD, they are also associated with other chronic 
inflammatory diseases, such as the rs10489629 vari-
ant with chronic periodontitis. In psoriasis, the vari-
ant rs11209026 has been described as a predisposing 
haplotype[17]. In both CD and psoriasis, treatment with 
an anti-p40 IL-12/23 antibody has shown promising 
results. Antibodies to the p40 subunit block both IL-12 
and IL-23, although in knockout mice studies, it has 
been proven that IL-23 drives chronic intestinal inflam-
mation[28]. Therefore, IL23R can serve as a therapeutic 
target in many different chronic inflammatory diseases, 
although the variants may differ among the different 
diseases. It is hypothesized that this is due to alternative 
mRNA splicing, which results in corresponding IL23R 
isoforms with different tissue distribution[28].   
IBD5	GENE
The IBD5 gene is about 250 kb and is located at position 
5q31. During a genome-wide linkage analysis, mapping 
studies have identified a risk haplotype within the IBD5 
locus. Many studies have linked this gene and its two vari-
ants, SLC22A4 (OCTN1) and SLC22A5 (OCTN2), to CD. 
IBD is believed to originate from an uncontrolled mucosal 
immunity of  the GI tract[17]. Although these variants are 
associated with CD, they act independently because there 
is no statistical evidence for interaction between IBD5 and 
the IL23R, ATG16L1 or CARD15 genes[12]. 
CTLA4 VARIANTS	
The CTLA4 gene is a member of  the immunoglobulin 
superfamily and is expressed on the surface of  helper 
T cells. It is located within the 2q33 region, translates 
into a protein that plays a role in the immune system, 
and may have a genetic association with IBD. It is a 
T-cell suppressor, which is essential in the function of  
the CD25+ CD4+ regulatory cells[7]. These regulator cells 
control the process of  intestinal inflammation. Many 
SNPs have been studied within this gene and it has been 
found that the rs3087243 variant shows the most asso-
ciation with IBD followed by the rs11571302, rs7565213 
and rs11571297 variants[35]. Although studies have shown 
that the three variants in the CTLA4 gene, g.49A > G 
(rs231775), g.-318C > T (rs5742909), and rs3087243, 
have no association with CD, other work has suggested 
that these variants may control the phenotype of  CD[14]. 
A study performed by Hradsky has shown no crude 
association between CD and SNPs within the CTLA4 
gene[12]. The study explored the possibility of  interactions 
in CTLA4 SNPs with variants in IL23R and NOD2. The 
R-project package SNPassoc was used and significant 
interactions between the three CTLA4 variants with 
NOD2 p.Leu1007fsX1008 and IL23R rs11209026 were 
observed[12]. This may be due to complex gene-gene inter-
actions. To characterize further the different variants and 
whether they determine phenotype in CD patients, the 
study used a case-only design. They observed a difference 
of  minor allele frequency at the rs3087243 gene between 
pediatric-onset and adult-onset of  CD[12]. It seems that a 
genetic factor has a greater impact in early-onset patients 
when compared to the adult-onset patients[38]. Within this 
study, the age of  diagnosis and localization of  the disease 
was strongly associated with the rs3087243, rs11571302 
and rs11571297 variants[12]. 
NOD2,	IL23R,	OCTN1/2	AND	ATG16L1	
POLYMORPHISMS	
Gene-gene interactions 
Interactions of  the major IBD alleles show a high sus-
ceptibility in CD patients. Gene-gene interaction can ei-
ther enhance or weaken the effects of  an individual gene, 
therefore making it more important than independent 
studies looking into the effects of  single susceptibility 
genes. Csongei and colleagues have performed a gene-
gene interaction analysis in the Hungarian CD popula-
tion[5]. They concentrated on the two IL23R gene risk 
variants (rs2201841 and rs1004819), the ATG16L1 gene 
variant (Thr300Ala), and the three NOD2/CARD15 
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variants (rs2066844, L1007fs and rs2066845). Logistic 
regression analysis showed that the IL23R variants, both 
rs1004819 and rs2201841 and the NOD2/CARD15 
variants (rs2066844 and L1007fs) conferred significant 
risk for CD. When the patients were homozygous for 
IL23R (rs1004819 and rs2201841) variants or ATG16L1, 
there was a highly increased risk for CD. When they 
analyzed possible statistical interactions between pairs of  
ATG16L1, IL23R and CARD15 variants, no evidence 
of  interactions was found. Therefore, all examined loci 
contribute independently to CD risk. Although sig-
nificant statistical interactions were not detected, these 
susceptibility factors may have a cumulative effect in the 
Hungarian population. 
Further gene-gene interaction studies have been 
performed in another population study, as well as as-
sessment of  CD genetic risk factors. The study included 
five SNP variants for IL23R, the functional variants 
SLC22A4 and SLC22A5, and the ATG16L1 mis-sense 
risk polymorphism Thr300Ala. All the SNPs, except 
for rs1495965 of  IL23R, showed significant association 
when carriers were either homozygous or heterozygous 
for the alleles[2]. Among them all, rs10889677 of  IL23R, 
showed the strongest association with CD risk[2]. Un-
surprisingly, ATG16L1 also showed a strong association 
with CD[2]. None of  the SNPs showed an association 
with UC. When they evaluated correlations between gen-
otype and phenotype for intestinal complications, carri-
ers of  the rs7517848 allele of  IL23R, particularly those 
who were homozygous for the allele, were found to be 
at risk for ileal disease. No other SNPs showed differ-
ences in genotype or carrier frequencies when compared 
to CD patients and their history of  complications. 
Homozygote variants from the IBD5 and ATG16L1 
genes had a greater risk than heterozygotes, suggesting 
a gene dosage effect[2]. When SNPs were considered 
two at a time, the best interactions were shown between 
IL23R_rs10889677 and IBD5_rs17622208, which 
were not statistically significant[2]. However, when us-
ing a logistic regression approach between these two 
markers, the IBD5_rs17622208 risk was only signifi-
cant in the presence of  the IL23R_rs10889677 risk 
allele[2]. When SNPs were considered three at a time, 
the model suggested statistically significant interactions 
between IL23R_rs10889677, IBD5_rs11739135, and 
ATG16L1_rs2241880[2]. When SNPs were considered 
four at a time, the model suggested interaction between 
IL23R_rs2201841, IL23R_rs7517847, and IBD5_ 
rs11739135[2]. A study in Oxford, UK has hown that 
certain IL23R polymorphisms have an association with 
CD only when the person is positive for IBD5[2]. In con-
clusion, the logistic regression model did not show any 
significant evidence of  gene-gene interaction, due to the 
small size of  the study, even though there was a consis-
tently small association between IBD5 and IL23R.
Childhood- vs adult-onset CD
The pathogenesis of  pediatric and adult IBD differ. 
The age of  childhood and adult onset varies between 
cultures to culture because different cultures base it on 
different aspects such as physical, mental, or puberty. 
North American studies choose an age cut-off  of  18 
years, and < 18 years is considered a child, even though 
an individual at this age is physically mature. This is why 
Canadian studies have chosen to describe a child as < 
16 years old. The belief  is that the lower the age cut-off, 
the better the results are when comparing pediatric and 
adult onset of  disease. Recent studies have shown that 
a subgroup of  patients with early-onset IBD may have 
specific phenotypes that differ from adult-onset IBD[39]. 
Many believe that pediatric-onset IBD is influenced by 
genetics compared to adult onset because there is less 
time for exposure to environmental modifiers to influ-
ence the onset of  disease. Adult-onset is probably due 
to a mixture of  genetics and abundant environmental 
exposure[25]. For example, smoking is a major variable in 
adult IBD patients, but has little influence on pediatric 
IBD cohorts. Currently, there are conflicting studies on 
whether NOD2/CARD15 polymorphisms are associ-
ated with the age of  onset of  IBD because some show 
an association towards a younger age, while others show 
no effect[40]. 
A study by Gazouli et al[25] has investigated the main 
polymorphisms and their association with childhood-
onset of  CD in a Greek cohort. While investigating the 
genotype and allele frequencies of  the NOD2/CARD15 
polymorphisms, rs2066844, rs2066845 and 3020insC, 
a statistically significant association between rs2066844 
and adult-onset CD was observed. In both pediatric- and 
adult-onset CD, individuals with at least one NOD2/
CARD15 polymorphism showed a genotype-phenotype 
correlation with ileal involvement[25]. The study also con-
firmed the recently described association between IL23R 
variants in both child- and adult-onset CD[35]. There 
has been conflicting evidence in studies regarding the 
ATG16L1 SNPs. One study has shown no association 
with early-onset or adult-onset CD[25]. Recent research 
has indicated that the ATG16L1 rs2144880 variant is 
associated with adult-pediatric-onset CD, whereas other 
studies have demonstrated an association with diagnosis 
at an earlier age[25]. In conclusion, the 3020insC variant 
in the NOD2/CARD15 gene is associated with CD and 
occurs considerably more often in childhood- than in 
adult-onset patients with CD[25].  
There is growing evidence that pediatric-onset IBD 
shows distinct differences when compared to its adult 
counterpart. Familial aggregation studies have shown an 
age-adjusted risk of  developing IBD in first-degree rela-
tives of  affected individuals compared to the general pop-
ulation[23]. The risk increases to > 30% for children when 
both parents are affected with IBD, suggesting that fam-
ily history is the strongest risk factor[5]. This is especially 
true among CD patients. Familial cases of  CD occur at a 
younger age with greater severity than random sporadic 
cases[36]. One main difference observed between pediatric- 
and adult-onset is that early onset shows a distinct and 
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more aggressive phenotype, such as the need for surgery, 
than similar IBD in individuals > 20 years old[41].  
Although NOD2/CARD15 mutations are neither 
sufficient nor necessary for the development of  IBD, 
they are associated with a younger age of  onset, pres-
ence of  ileal involvement, and the development of  
strictures[23]. There is also a gene dosage effect for CD 
location and complications. For example, stricture com-
plications occur more frequently in CD children with the 
1007fs mutation in the NOD2/CARD15 gene compared 
to children without this variant due to early surgery[42]. 
Therefore, children with this mutation have a sixfold in-
creased risk for developing a stricture complication[23].   
There has been conflicting evidence among studies 
that have attempted to show a link between the IBD5 lo-
cus and early-onset CD. A study by Rioux has found that 
the IBD5 locus is associated with early-onset CD where 
children were defined with an age of  onset of  < 16 years 
old[23]. However, studies from pediatric-onset CD co-
horts have demonstrated that the risk of  IBD5 is lower 
compared to that in adult-onset CD, while others have 
demonstrated enhanced risk of  developing CD when an 
individual has both SLC22A4-A5 and NOD2/CARD15 
mutations[43]. This connection may be due to a common 
pathophysiological mechanism[23].  
Although there is no sex difference among patients 
with adult-onset IBD, there is a clear and distinct dif-
ference among children with CD. Many studies from 
pediatric CD cohorts in the United States, Canada and 
the United Kingdom have shown an increase in male in-
cidence. The higher male to female ratio continues to be 
unexplained. These differences are not observed among 
UC pediatric patients[23]. It seems that sex is an age-
dependent variable that has more influence on children 
than adults with IBD. 
There are also phenotypic differences, such as disease 
location, among children and adult CD. For example, in-
creased rates of  upper GI tract disease and pure colonic 
disease in pediatric-onset CD have been identified. This 
difference may be due to the amount of  examination 
during the onset of  disease. Children undergo extensive 
GI endoscopy, whereas adults do not[23]. These findings 
may be artificial or represent a true disease distinction 
among children and adults. Another distinction is the 
occurrence of  colon-predominant disease during child-
hood-onset IBD under the age of  10 years old. With 
children < 5 years old, all have colon-only disease[44]. 
During a study of  approximately 1400 North American 
early-onset patients, data showed a colon-predominant 
phenotype in children < 8 years old. In another study in 
Europe, the acquisition of  ileal CD became increasingly 
common as an individual approached 16 years old[23]. 
These data confirm an association of  colon-predomi-
nant phenotype in early diagnosed children that changes 
as they grow older. 
Population studies with NOD2, IL23R and ATG16LI 
polymorphisms  
NOD2, IL23R and ATG16L1 polymorphisms were stud-
ied in a Lithuanian cohort with IBD. The study included 
57 unrelated patients with CD, 123 with UC and 186 
healthy individuals as controls. The three NOD2 vari-
ants, the IL23R variant rs11209026, and the ATG16L1 
variant Thr300Ala, were genotyped among the popula-
tion sample. No individuals were carriers of  all three 
NOD2 risk alleles, whereas two CD patients were com-
pound heterozygotes[10]. Carriers of  at least one NOD2 
variant were highest among CD patients[10]. There were 
no significant differences observed between UC patients 
and the controls. The NOD2 variant, Leu1007insC, 
was significantly associated with increased susceptibil-
ity in the Lithuanian CD population[10]. In comparison 
to the other two NOD2 variants, the frequencies were 
very low and not significant in controls and among the 
IBD patients[10]. In contrast to other European studies, a 
positive association between rs2066844, rs2066845 and 
CD was not found[10]. When they further tried to analyze 
IL23R and ATG16L1, they were unable to replicate pre-
vious findings of  increased susceptibility to IBD within 
the Lithuanian population[10]. They were was a trend for 
a possible association with the ATG16L1 risk allele[10]. It 
is of  particular interest to study this population because 
Baltic countries have low IBD incidence rates, especially 
for CD. To confirm distinct IBD subtypes, a study using 
a larger North-Eastern European IBD sample needs to 
be investigated. 
Another population study was performed among 
New Zealand Caucasians with IBD. Their cohort in-
cluded 466 UC patients, 496 CD patients and 591 
controls. All individuals were genotyped for the IL23R 
rs11209026 SNP, the ATG16L1 rs2241880 SNP, and the 
CARD15 variants. Significant interaction was detected 
between variants in ATG16L1, IL23R and CARD15 
and CD susceptibility, whereas no significant association 
was observed between IL23R or ATG16L1 genotypes 
and IBD sub-phenotypes[37]. The strongest association 
occurred between the ATG16L1 rs2241880 variant and 
CD, with no association detected with UC[37]. ATG16L1 
is suggested to have a CD-specific susceptibility locus. 
Unlike ATG16L1, the IL23R rs11209026 variant was 
strongly associated with both CD and UC. In their 
patient cohort, there was no evidence that IL23R or 
ATG16L1 genotypes influenced disease behavior, age 
of  onset, location, or the need for surgical bowel resec-
tion[37]. On the other hand, CARD15 was consistently 
a susceptibility factor and predictor of  CD phenotype. 
Similar to many other studies, all three CARD15 SNPs 
are significantly overrepresented in patients with IBD 
family history, early onset of  disease, ileal disease in-
volvement, and development of  complications[33].  
Interactions between NOD2 and IL23R variants with toll-
like receptor-9 polymorphisms 
Toll-like receptors (TLRs) are single, membrane-span-
ning proteins that play a key role in the innate immune 
system. These receptors recognize microbes that have 
structurally conserved molecules that breach the physical 
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barriers. Once bound, TLRs activate the immune system. 
The responsiveness of  the GI tract to luminal bacteria is 
dependent on the interaction of  transmembrane TLRs 
and the intracellular NOD2 receptor[18]. Specifically, 
TLR9 plays a role in the maintenance of  intestinal in-
flammation in IBD. TLR9 is also responsible for stimu-
lating NOD2, which in turn enhances innate immune 
responses. Patients with two NOD2 mutations lose the 
synergistic affect between NOD2 and TLR9 stimulation. 
Therefore, interactions of  both receptors have implica-
tions for intestinal homeostasis and inflammation[18]. The 
TLR9 gene is located on chromosome 3p21.3, which 
is close to other CD susceptible loci[9]. There are four 
SNPs in TLR9, but two of  them are sufficient to distin-
guish between the haplotypes, which are rs5743836 and 
rs352140. 
There might be a synergistic effect of  NOD2 and 
TLR9 stimulation, therefore, Torok and colleagues have 
tested for gene interactions between TLR9 and CD-
associated variants of  NOD2[18]. Significant associations 
between the two were observed that were specific to 
CD[18]. The controls and UC showed no difference in 
distribution of  TLR9 polymorphisms and NOD2 vari-
ants[18]. Other CD variants in IL23R, ATG16L1 and 
IBD5 were analyzed for epistatic interactions. Aside 
from NOD2, the most significant association was found 
in the IL23R variant rs1004819, with ATG16L1 showing 
weaker associations with CD. There was no significant 
association between TLR9 polymorphisms with CD or 
UC phenotypes[18]. Along with previous studies, they 
also showed that NOD2 mutations were associated with 
younger age of  diagnosis of  CD, ileal disease, and need 
for surgery[18]. When there were two NOD2 mutations, 
there was a higher frequency of  penetrating disease[18]. 
In conclusion, a new association between CD and a 
TLR9 polymorphism has been found. There is evidence 
that when CD patients carry CD-associated NOD2 
variants, they have an increased incidence of  TLR9 
polymorphisms. This is not surprising because there 
is a synergistic effect of  NOD2 and TLR9 stimulation 
and it is important for the maintenance of  intestinal 
homeostasis and inflammation. TLR9 also demonstrates 
significant epistatic interactions with IL23R variants, but 
unlike NOD2, there is no association with the frequency 
in TLR9 polymorphisms present. This study shows the 
first evidence for interaction between polymorphisms in 
TLR9 and variants between NOD2 and IL23R[18]. 
CONCLUSION 
CD is an autoimmune disease characteristic of  chronic 
intestinal inflammation and lesions. It can affect people 
of  all ages and ethnicities worldwide. Recent genome-
wide studies have shown significant genetic associations 
of  several variants and susceptibility to CD. This is true 
for North American, South American and European 
populations. Certain variants have been linked only to 
Asian and African cohorts. It is vital to understand the 
pathology of  CD and the underlying genetic interactions 
to increase efficiency of  diagnosis and develop drugs 
that target specific immune system pathways. There have 
been several genetic variants highly associated with CD, 
which include ATG16L1, TNFSF15, NOD2/CARD15, 
IL23R and IBD5 (Table 1). 
The process of  autophagy is an important aspect of  
our immune system. It is a way to destroy foreign patho-
gens that enter the body. The Thr300Ala variant within 
the N terminus of  ATG16L, which is part of  a complex 
that forms autophagosomes, has significant associations 
with CD. Different ethnicities show different genotype 
markers. This is seen in TNFSF15, which is involved 
in systemic inflammation and regulation of  various im-
mune cells. Seven haplotypes have been identified within 
a Japanese cohort, but not in other ethnic cohorts. More 
research needs to be conducted to characterize fully this 
possible genetic link to CD. The most significant asso-
ciation with CD is observed among NOD2/CARD15 
and IL23R variants. NOD/CARD15 plays an essential 
role in maintaining the intestinal normal flora. There are 
many theories about the cause of  CD, and one of  them 
includes a shift in the intestinal bacterial flora. There-
fore, it is no surprise that NOD2 variants are highly as-
sociated with CD. There are three independent variants 
associated with CD: rs2066844, rs2066845 and 1007fs. 
The other highly associated genetic link is observed 
within the IL23R gene. One variant that is highly associ-
ated with CD is rs1004819, whereas rs11209026 confers 
protection against CD. IL23R plays an essential role in 
  Gene     Polymorphism    Relationship significance   Ref.
  ATG16L rs2241880 Associated with ileal form of CD with or without colonic involvement [4,12]
Thr300Ala Highly associated with CD
  NOD2/CARD15 rs2066844, rs2066845, 3020insC, 1007fs Independently associated with CD [20]
  IBD5 SLC22A4 (OCTN1), SLC22A5 (OCTN2) Independently associated with CD [12]
  CTLA4 rs3087243, rs11571302, rs11571297, rs7565213 Associated with IBD; no crude association to CD [35]
  TNFSF15 80 000 SNPs tested, including 7 SNPs 
within a 280 kb region on chromosome 9q32
Strongly associated with CD for Japanese and Jewish cohorts, 
but not for Europeans
[4,15,16]
  IL23R rs11209026 Strongly associated with conferring protection against CD [4,33]
rs1004819 Highly associated with CD
Table 1  Key gene polymorphisms and their significance in Crohn’s disease
SNPs: Single-nucleotide polymorphism; CD: Crohn’s disease.
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mediating proinflammatory activities. Another highly as-
sociated genetic link with CD is observed in two variants 
within IBD5. The two variants, SLC22A4 (OCTN1) and 
SLC22A5 (OCTN2), show significant association with 
CD, but no interactions between these variants and other 
CD-associated genetic variants have been observed. The 
last highly associated genetic link with CD is observed 
within the CTLA4 gene. This gene plays a role in the 
immune system. The four polymorphisms associated 
with IBD are rs3087243, rs11571302, rs7565213 and 
rs11571297.
Many CD variants are associated with a specific CD 
phenotype, age of  diagnosis, severity and location of  
CD, and surgical outcome. Gene-gene interactions have 
also been characterized among the different variants and 
other immune system receptors. We need to understand 
fully the pathogenesis of  CD to target pathways for ef-
fective treatment. Further research is needed to explore 
all possible gene-gene interactions due to a gene dose 
affect associated with CD. It seems that new genetic as-
sociations are constantly being uncovered within IBD 
and then associated with either CD or UC. Overall, CD 
shows a greater genetic link than UC. Recent discover-
ies have led to therapies and treatments that show much 
promise. Researchers need to continue the search for 
genetic links and diseases because this may be the only 
way to understand the pathology of  CD and develop ef-
fective treatments. 
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